Asklepios BioPharmaceutical Enters into License Agreement with Calimmune


CHAPEL HILL, N.C.–Asklepios BioPharmaceutical, Inc. (AskBio) has entered into a license agreement granting Calimmune Inc. rights to AskBio’s Adeno-Associated Virus (AAV) gene therapy technologies. Calimmune, a gene therapy company focused on enhancing patients’ immune systems to defeat disease, plans to utilize these technologies in a forthcoming Phase I/II clinical trial to evaluate the safety and efficacy of a potential gene therapy for the treatment of osteoarthritis. Currently over 27 million Americans suffer from osteoarthritis, a chronic, degenerative disease of the joints, which is incurable and difficult to treat.

Subscribe to get the latest news